Figure 4. | Laboratory Investigation

Figure 4.

From: Characterization of a Novel Breast Carcinoma Xenograft and Cell Line Derived from a BRCA1 Germ-Line Mutation Carrier

Figure 4.

Expression of BRCA1 protein by immunoprecipitation and Western blotting using the mAb MS-110. a, Lanes 1 and 2 show L56Br-X1 and the wild-type control (breast cancer cell line HBL-100), respectively, where BR1S060.2 (10 μg) was used to immunoprecipitate BRCA1 proteins from the lysates. B, Lanes 1 and 2 show L56Br-X1 and the wild-type control (breast cancer cell line HBL-100), respectively, where MS110 (6 μg) was used to immunoprecipitate BRCA1 proteins from the lysates. Gray arrows indicate the position of BRCA1 220 kd. Lanes 3 and 4 show L56Br-X1 and the control HBL-100 cell line at the position of 63 kd (black arrow), where the truncated BRCA1 protein of 563 amino acids resulting from the mutation Q563X is expected to migrate.

Back to article page